Contract Option Exercises — February 03, 2026

Two firm-fixed awards (GSA $277M, NIH $180M) with $144M outlayed (33% progress) position firm for institutional building revenue through 2028.

GD IT ($196M, 51% outlayed) and Emmes ($169M, 70% outlayed) deliver steady CMS/NIAID support services, with $220M progressed signaling low execution risk.

ATI's $304M nonprofit award under BIOMAP shows $11M outlay (4%) with $72M options unexercised, indicating measured federal health R&D funding.

Firm-fixed pricing on $457M Hensel Phelps contracts exposes to construction cost overruns amid low initial outlays ($21-32%).

Long-dated HHS awards to 2027-2028 ($848M total) vulnerable to budget shifts or audits on cost-plus/T&M structures.

$191M unexercised options across ATI ($72M), GD ($2M), Emmes ($117M) offer upside to $1.32B total ceiling.

NIH/NIAID lab expansions and infectious disease data centers signal multi-year health infrastructure buildout.

75% of $1.13B flows to HHS for labs, data coordination, and biotech manufacturing, with 45% outlayed on average.

$457M firm-fixed awards for specialized facilities (labs, LPOE) with full obligations provide backlog certainty.

{"entity"=>"Hensel Phelps Construction Co.", "reason"=>"$457M exposure (40% of period total) with dual-agency wins signals follow-on potential.", "trigger"=>"Outlays exceed 50% by Q2 2026 or new awards >$100M"}

{"entity"=>"HHS Budget Allocations", "reason"=>"Dominates 75% value; long tenors amplify funding sensitivity.", "trigger"=>"FY2027 appropriations cuts or BARDA/CMS option exercises"}

{"entity"=>"The Emmes Company, LLC", "reason"=>"70% outlay on $169M NIAID award with $117M options offers largest relative upside.", "trigger"=>"Options exercised pushing value to $287M"}